SPYRE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
SPYRE THERAPEUTICS, INC. (SYRE) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $903.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $903.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $432.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $180.96M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $39.47M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $903.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $432.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $180.96M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $39.47M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $170.61M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $105.15M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $249.26M 10-K · filed 2026-02-19 |
| 2024-09-30 | $37.57M 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $309.20M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $183.21M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $14.74M 10-K · filed 2025-02-27 |
| 2023-09-30 | $97.19M 10-Q · filed 2023-11-09 |
| 2023-03-31 | $993.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $25.17M 10-K/A · filed 2024-11-18 |
| 2022-09-30 | $35.93M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $66.30M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $55.09M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $60.00M 10-K · filed 2023-03-02 |
| 2020-12-31 | $110.08M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |